Marksans Pharma Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n5z7ndgc39bhkxwh9l8dz4mb.pdf

Key Takeaways


Teva Plant Acquisition & Integration

Mark Saldanha: "So obviously reason is because we have the Teva acquisition there, which we have done. And we'll be integrating this acquisition on 1st of April. So there were too many things to juggle. So we decided to go down this route, number one, I do believe it will be more economical."

Margin Dynamics & Cost Relief

Mark Saldanha: "That was a big burden, which was difficult - because freight is a very variable factor. So it's difficult to pass it on to our client or something of that stuff, because it may go up and may come down. So you can't keep going into the client saying, well, it's gone up one day, it's come down the other day."

US Market & Competitive Dynamics

Mark Saldanha: "Honestly, companies get a bit desperate in terms of pricing. But that said and done, we are confident of achieving our objectives and hitting our forecasted numbers."

Rx-to-OTC Strategy

Mark Saldanha: "It is driven by the regulatory primarily, but it's a push from bigger companies that go on, and instead of waiting and watching, you need to be more alert as to what's happening in the market... based on the probability factors, we need to start working well in advance, so that we don't miss the bus on the early-to-market strategies."

Backward Integration & API Strategy


Balance Sheet, Cash & Inorganic Growth

Mark Saldanha: "M&A is a very tricky thing, but if past history has taught us anything, I mean if you look at our track records, we have done over four M&As over the span of a decade and a half. ... we have marathon discussions that puts valuable because they do give us insights of the company, the financial backgrounds, and analytic evaluations that they run through."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue milestoneCross Rs. 2,000 croresFY24
EBITDA marginMaintain margin, if not slightly improveFY24
Teva plant breakevenBreakeven operations~9 months from 1 April 2023 entry
Teva plant capex~INR200 crores overall (including upfront payment)Deployment during integration phase
Teva plant revenueDecent, sizable revenue from Teva~12 months down the line
Freight cost margin benefitMargin improvement of slightly one-plus percentQ4 FY23 onwards
Raw material cost benefitLower input costs flow throughPost ~6 months (once high-cost inventory clears)
Backward integration margin impact200–300 bps expansionAs DMFs are filed and commercialized (~1.5 years)
DMF filingsAt least 2–3 DMFs filedCalendar year 2023

Key Metrics

MetricQ3 FY23
Operating revenue₹479.8 cr, +32.3% YoY
US & North America revenue₹217.0 cr, +37.8% YoY
EU & UK formulation revenue₹186.8 cr, +25.4% YoY
Australia & New Zealand revenue₹49.6 cr, +27.6% YoY
Rest of World revenue₹26.5 cr, +52.0% YoY
Gross margin50.1%, declined 371 bps YoY from 53.8%
EBITDA₹76.6 cr, +32.6% YoY
EBITDA margin16.0%, stable YoY
Profit after tax₹62.3 cr, +29.1% YoY
EPS₹1.56, +30% YoY
Net cash position₹417 cr, debt-free as of 31 Dec 2022; excludes ₹279 cr warrant subscription received Jan 2023
R&D spend (9M FY23)₹24.5 cr, 1.8% of sales
US business QoQ growth~12%
Own-label brands share15% to 20% of OTC business
Inventory~₹450 cr as of 31 Dec 2022
Working capital cycle~150 days as of Dec 2022
Issued share capital~45 cr shares post-warrant conversion and buyback
FY24 revenue guidanceCrossing ₹2,000 cr
Teva plant capex budget~₹200 cr, including upfront acquisition payment
Teva plant breakeven timeline~9 months from integration starting 1 Apr 2023
UK pipeline34 new filings planned over next 3 years; 7 planned in CY2023; 16 already filed or awaiting approval
US pipeline32 products in pipeline; 20 solid oral, others in ointments, creams, soft gels
DMFs in development10 DMFs; at least 2-3 to be filed in 2023
Freight cost margin benefit expectedSlightly 1%+ margin improvement from Q4 onwards